B kinase (IKK) inhibitor (IC50
= 100 nM). Has no effect on PKA, PKC and CKII activity. Inhibits Iκ
phosphorylation and NFκ
B activation in HeLa cells. Inhibits NFκ
B-mediated proinflammatory gene expression in human airway epithelial cells. Enhances TNF-α
-induced apoptosis in a multiple myeloma cell line. Attenuates LPS-induced TNF-α
production in vivo
. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Novel IKK inhibitors: beta-carbolines.
Castro et al.
Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.
Newton et al.
NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima et al.